Evolent Health Q1 revenue $639.7M (+49.6% YoY); raises FY2024 revenue guide

Evolent Health, Inc.

2024-Q1 EPS reported -$0.22 revenue$639,653,000

Revenue $639.7M, net loss $(25.2)M; Adjusted EBITDA $54.1M (8.5% margin).
Raises full-year 2024 revenue outlook; reiterates Adjusted EBITDA and exit-rate guidance.
Ends NIA transition services agreement; partners with Careology to accelerate patient navigation.
New Performance Suite with Molina for oncology/cardiology in SC and MS; MSK contract with east coast Medicaid plan.
Performance Suite average lives 7,050 (up from 3,242 YoY); specialty care revenue grew over 60%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolent Health, Inc. reported the quarter ended March 31, 2024 results: revenue $639.7 million, net income $(25.2) million. Guidance raised.

Period: the quarter ended March 31, 2024
Revenue: $639.7 million
Net income: $(25.2) million
Guidance: raised
Result: reported results

Exact text from the filing

Evolent Announces First Quarter 2024 Results • Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Evolent Health, Inc. filing history →

Source: SEC EDGAR

accession 0001628908-24-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.